

SALUBRITY BIOTECH LIMITED

Registered Office: Unit No. B.06.08, NBCC Vibgyor Tower, New Town, Rajarhat, Kolkata, West Bengal - 700156
CIN No: L24100WB1990PLC048591

STATEMENT OF UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31-03-2024

(In Lakhs)

Particulars	Quarter Ended			Year Ended	
	31-03-2024 Audited	31-12-2023 Un-audited	31-03-2023 Audited	31-03-2024 Un-audited	31-03-2023 Audited
1 Income					
Revenue from operation	262.68	288.10	526.89	1,236.88	1,503.66
Other Income	1.67	0.66	2.00	11.72	7.99
Total Income	264.35	288.76	528.89	1,248.60	1,511.65
2 Expenses					
(a) Cost of Raw Material Consumed	305.70	96.30	227.90	970.03	904.54
(b) Purchase of Stock in Trade	-	-	-	-	-
(c) Change in Inventories of Finished Goods, Work-in-Progress and Stock in Trade.	-88.51	66.12	115.84	-64.02	157.27
(d) Employees Benefit Expenses	17.79	16.25	2.93	70.84	74.72
(e) Finance Costs	6.99	8.65	10.13	34.50	27.26
(f) Depreciation and amortisation expenses	7.63	7.63	7.55	30.52	30.19
(g) Other expenses	48.13	41.21	50.88	188.62	228.89
Total Expenses	297.73	236.16	415.21	1,230.49	1,422.87
3 Profit/ (Loss) before exceptional and extraordinary items and tax (1-2)	(33.38)	52.60	113.68	18.11	88.78
4 Exceptional Items	-	-	-	-	-
5 Profit/ (Loss) before Tax (3-4)	(33.38)	52.60	113.68	18.11	88.78
6 Tax Expenses	4.52	-	19.09	4.52	19.09
(a) Current Tax	4.52	-	23.18	4.52	23.18
(b) Deferred Tax	-	-	-4.09	-	-4.09
(c) Current tax expenses relating to earlier years	-	-	-	-	-
7 Profit (Loss) for the period (5-6)	(37.90)	52.60	94.58	13.59	69.69
8 Other Comprehensive Income					
(i) Items that will not be reclassified to Profit and Loss	-	-	-	-	-
(ii) Tax relating to Other Comprehensive Income	-	-	-	-	-
(iii) Other Comprehensive Income (Net of Tax)	-	-	-	-	-
9 Total Comprehensive Income for the Period (7+8)	(37.90)	52.60	94.58	13.59	69.69
10 Paid-up Equity Share Capital (Face Value Rs. 10/-)	300.00	300.00	300.00	300.00	300.00
11 Reserves excluding Revaluation Reserves as per Balance Sheet of Previous Accounting Year	231.05	217.46	217.46	231.05	217.46
12 (a) Basic Earning per Share (in Rs.)	-	0.18	0.32	0.05	0.23
13 (b) Diluted Earning per Share (in Rs.)	-	0.18	0.32	0.05	0.23

Notes:

- The Company has not followed INDIAN ACCOUNTING STANDARD (IND AS) method of accounting as required for all listed companies.
- Figures of the Previous period are regrouped, wherever necessary, to correspond with the Current Period's classification/disclosure
- This Statement is as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Salubrity Biotech Limited
Hariprasad Hariprasad
Managing Director

**By Order of the Board of Directors
For Salubrity Biotech Limited**

Place : Cuttack
Date : 05 May 2024


Chairman

SALUBRITY BIOTECH LIMITED
UNIT NO B.06.08, NBCC VIBGYOR TOWER NEW TOWN,
RAJARHAT KOLKATA, WEST BENGAL - 700156
CIN:U24100WB1990PLC048591

BALANCE SHEET AS AT 31ST MARCH 2024

(In Lakhs)

Particulars	Note No	As At 31-03-2024	As At 31-03-2023
A			
<u>EQUITY AND LIABILITIES</u>			
1			
Shareholder's Funds			
(a) Share Capital		300	300
(b) Reserves and Surplus		231	217
		531	517
2			
Non-Current Liabilities			
(a) Long Term Borrowings		51	53
(b) Long term Provisions		-	-
		51	53
3			
Current Liabilities			
(a) Short Term Borrowings		470	397
(b) Trade Payables		64	158
(c) Other Current Liabilities		-	9
(d) Short Term Provisions		5	23
		538	587
		1,120	1,158
Total Equity & Liabilities			
B			
<u>ASSETS</u>			
1			
Non Current Assets			
(a) Property Plant & Equipment		328	178
(i) Tangible Assets		-	-
(ii) Intangible Assets		-	-
(iii) Capital Work-in-Progress		-	-
(c) Deferred Tax Assets (Net)		6	6
(d) Other Non Current Assets		91	10
		425	194
2			
Current Assets			
(a) Inventories		340	325
(b) Trade Receivables		276	572
(c) Cash and Bank Balance		16	8
(d) Short-Term Loans and Advances		-	-
(e) Other Current assets		63	60
		695	965
		1,120	1,158
Total Assets			

Salubrity Biotech Limited

Manoj Kumar Agarwal
Managing Director

**By Order of the Board of Directors
For Salubrity Biotech Limited**

Place: Cuttack
Date: 05 May 2024

Chairman